NEW YORK (
TheStreet) --
CHANGE IN RATINGSBlack & Decker (BDK) downgraded at Barclays to Equal Weight from Overweight following SWK deal. Price target lifted to $62 from $57. 2009 and 2010 EPS estimates maintained at $2.44 and $2.84, respectively.
Cognizant Technology (CTSH) upgraded at Wells from Market Perform to Outperform. Estimates also raised, to reflect an acceleration in business trends.
Energizer (ENR) downgraded at Goldman from Buy to Neutral. $61 price target. Company is seeing lower margins, which could delay stock buybacks.
Content Continues Below
Select Medical (SEM) initiated at BofA/Merrill with a Buy rating and $13 price target. Huge upside from the company's JV initiatives. 2009 and 2010 EPS estimates set at $0.49 and $0.62, respectively.
Viacom (VIAB) price target increased at Barclays to $35 from $32 on 3Q beat. Reiterate Overweight rating. 2009 and 2010 EPS estimates increased to $2.32 and $2.45, respectively.
STOCK COMMENTS / EPS CHANGES
Archer Daniels Midland (ADM) numbers raised at Morgan Stanley to $33. Estimates also increased, to reflect the company's new guidance. Equal-weight rating.
American Eagle (AEO) added to Top Picks list at FBR. Company is poised to benefit from the plaid fashion trend. Outperform rating and $24 price target.
Anadarko Petroleum (APC) price target, estimates raised at Barclays. Price target surged to $66 from $45 after strong 3Q results. 2009 and 2010 EPS estimates raised to -$0.80 from -$2.00 and to $0.45 from -$0.15, respectively. Maintain Equal Weight rating.
Cardinal Health (CAH) price target lifted at Barclays by a dollar to $30. 2010 and 2011 EPS estimates tweaked to $1.95 and $2.15, respectively. Maintain Overweight rating.
Cameron International (CAM) estimates increased at Goldman through 2011. Company is seeing higher sales. Buy rating and $52 price target.
Church & Dwight (CHD) estimates boosted at Morgan Stanley through 2011. Company has strong business momentum and is gaining market share. Equal-weight rating and $64 price target.
Chesapeake (CHK) estimates raised at Goldman through 2011. Company positioned well to see improving returns over the coming quarters. Buy rating and $34 price target.
Cliffs Natural (CLF) numbers boosted at FBR. CLF estimates were raised through 2010. Company is realizing fixed cost leverage. Outperform rating and new $41 price target.
Cablevision (CVC) estimates, target upped at Goldman. Shares of CVC now seen reaching $24. Estimates also increased, to reflect higher realized margins. Neutral rating.
Discovery (DISCA) estimates lowered at UBS through 2010. Management gave cautious guidance and doesn't see much more cost cutting. Neutral rating and $33 price target.
Dolby (DLB) estimates, target boosted at Goldman. Shares of DLB now seen reaching $45. Estimates also raised, to reflect the company's new buyback program. Neutral rating.
Digital Realty Trust (DLR) price target raised at BofA/Merrill to $50 from $48 as growth of top customers should drive continued demand. Maintain Buy rating.
Davita (DVA) estimates boosted at UBS through 2010. Company is seeing higher sales and operating margins. Buy rating and $65 price target.
Emerson (EMR) estimates, target increased at FBR. Shares of EMR now seen reaching $38. Estimates also boosted, as demand appears to have bottomed. Market Perform rating.
Emergency Medical (EMS) numbers boosted at Goldman. Estimates were raised through 2011. Company is not being hit as hard by the economic weakness. Neutral rating and new $55 price target.
Energizer (ENR) price target, estimates slashed at BofA/Merrill. Price target to $67 from $75. 2009 and 2010 EPS estimates lowered to $5.08 and $5.31, respectively. Maintain Buy rating.
F5 Networks (FFIV) numbers increased at Goldman. Shares of FFIV now seen reaching $46. Estimates also boosted, to reflect higher realized sales and margins. Neutral rating.
Hartford Financial (HIG) numbers raised at FBR. Shares of HIG now seen reaching $26. Estimates also boosted, to reflect improving core growth. Market Perform rating.
Health Net (HNT) estimates, target increased at Citigroup. Shares of HNT now seen reaching $18. Estimates also boosted, to reflect longer Tricare business operations. Hold rating.
MasterCard (MA) estimates, target increased at Citigroup. Shares of MA now seen reaching $250. Estimates also boosted, to reflect higher prices and cost-cutting progress. Hold rating.
MasterCard (MA) price target boosted at Barclays. MA price target lifted to $272 from $266 as weakness is buying opportunity. 2009 and 2010 EPS estimates increased to $11.29 and $13.60, respectively. Reiterate Overweight rating.
Medco Health (MHS) numbers raised at Goldman. Shares of MHS now seen reaching $63. Estimates also boosted, to reflect higher expected sales and share buybacks. Neutral rating.
Martin Marietta (MLM) estimates lowered at UBS. MLM estimates were reduced through 2010. Recovery is delayed, as management has poor visibility. Neutral rating and $102 price target.
Myriad Genetics (MYGN) estimates cut at Morgan Stanley through 2011. Company is seeing higher operating expenses. Equal-weight rating.
O'Reilly Automotive (ORLY) estimates raised at FBR. ORLY estimates were increased through 2010. Underperform rating.
Och-Ziff (OZM) estimates, target raised at Goldman. OZM estimates were boosted through 2011. Company is seeing higher asset flows and lower costs. Buy rating and new $15 price target.
Royal Caribbean (RCL) estimates raised at UBS. RCL estimates were increased through 2010. Company raised its yield guidance. Neutral rating and $24 price target.
Royal Caribbean (RCL) target higher, estimates changed at Barclays. RCL price target raised to $18 from $15. 2009 EPS cut to $0.69 from $0.75, 2010 increased by a quarter to $1.50. Maintain Equal Weight rating.
Rowan (RDC) estimates, target increased at Goldman. Shares of RDC now seen reaching $29. Estimates also raised, to reflect better drilling performance and a lower tax rate. Neutral rating.
Polo Ralph Lauren (RL) numbers raised at Goldman. RL estimates were increased through 2011. Company guided higher and further sales upside is possible. Buy rating and new $92 price target.
Teva Pharma (TEVA) estimates raised at UBS. TEVA estimates increased through 2010. Company continues to execute through a difficult economic environment. Buy rating and $60 price target.
Viacom (VIAB) estimates, target boosted at Goldman. VIA.B estimates were raised through 2011. Company is seeing higher Media Networks margins. Buy rating and new $35 price target.
Vulcan Materials (VMC) estimates cut at UBS. VMC estimates were lowered through 2010. Stimulus is not hitting the numbers as quickly as expected, and wet weather hurt the company last quarter. Neutral rating and $57 price target.
U.S. Steel (X) estimates raised at Morgan Stanley. X estimates were increased through 2010. Steel prices should find support. Equal-weight rating and $53 price target.
© 1996 -
2009 TheStreet.com, Inc. All rights reserved.
Most Read Articles from TheStreet.com
Black Friday's 10 Top Tech Deals
A review of black Friday deals from Apple, Hewlett-Packard, Garmin, Palm and others.
Motorola Droid Price Cut
Motorola's Droid lands at Verizon, discounts follow days later.
Dividend Stocks for the Week
These companies, including Nike and Campbell Soup, recently boosted their dividend payouts.